Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Total Current Liabilities (2018 - 2025)

Nanobiotix has reported Total Current Liabilities over the past 8 years, most recently at $66.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 6.29% year-over-year to $66.9 million; the TTM value through Dec 2025 reached $66.9 million, up 6.29%, while the annual FY2025 figure was $66.9 million, 6.29% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $66.9 million at Nanobiotix, down from $71.4 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $71.4 million in Q2 2025 and troughed at $38.7 million in Q4 2022.
  • A 5-year average of $54.2 million and a median of $54.0 million in 2023 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 85.66% in 2021 and later decreased 8.17% in 2022.
  • Year by year, Total Current Liabilities stood at $42.1 million in 2021, then dropped by 8.17% to $38.7 million in 2022, then soared by 38.64% to $53.7 million in 2023, then increased by 17.36% to $63.0 million in 2024, then grew by 6.29% to $66.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for NBTX at $66.9 million in Q4 2025, $71.4 million in Q2 2025, and $63.0 million in Q4 2024.